SLU-PP-915 / Study library
Filter by study model, then open the original record to examine methods and findings.
3 studies shown
The study identified SLU-PP-915 and connected its receptor activity to changes in ERR target-gene expression. It also examined metabolic stability during chemical optimization.
Reading limit: This is early pharmacology and compound development. It does not establish clinical effectiveness, a human exposure target, or long-term safety.
Investigators reported increased treadmill performance with oral SLU-PP-915 and compared responses with SLU-PP-332 after accounting for systemic exposure. They also examined gene-expression changes alongside exercise training.
Reading limit: Oral activity in mice is not a demonstration of human oral effectiveness or equivalence with a particular capsule product.
The researchers identified TFEB as a direct ERR-regulated gene and found increased TFEB-related expression after ERR activation. SLU-PP-915 was used to investigate this connection in cell preparations.
Reading limit: Cellular pathway measurements do not establish clinical rejuvenation, disease prevention, or a lifespan effect.
We reviewed the linked primary publications and source records for the claims summarized here. This is a focused educational selection, not a systematic review or a clinical recommendation. Scientific findings are kept separate from supplier catalog descriptions.
The selected evidence comes from laboratory and animal studies. It does not establish human efficacy, an appropriate human-use protocol, or the safety and performance of a commercial formulation. SLU-PP-332 and SLU-PP-915 are distinct molecules and should not be treated as interchangeable.
Confirm molecular identity, batch identification, analytical methods and the actual formulation before relating a commercial material to a publication. A purity percentage alone does not establish all of those facts.
Visit Disguised Alpha or read the extended compound profile.
